Zobrazeno 91 - 100
of 127
pro vyhledávání: '"Elizabeth I. Buchbinder"'
Autor:
Osama E. Rahma, Elizabeth I. Buchbinder, Amitabh Srivastava, Sonia Friedman, Shilpa Grover, F. Stephen Hodi
Publikováno v:
Journal of Clinical Oncology. 37:2582-2582
2582 Background: Colitis is a frequent toxicity of ICI therapy but there is paucity of data on risk factors. Specific serological markers and genetic polymorphisms have been associated with inflammatory bowel disease (IBD) (ulcerative colitis, Crohn
Autor:
Kai W. Wucherpfennig, Aviv Regev, Shruti Malu, Gao Zhang, Adam N.R. Cartwright, Parin Shah, Jia-Ren Lin, Rohit Thummalapalli, Shu Wang, Levi A. Garraway, David A. Barbie, Rachel Leeson, Marie-Andree Forget, Tabea Moll, Johannes M. Melms, David Liu, Adrienne M. Luoma, Orr Ashenberg, Eliezer M. Van Allen, Peter K. Sorger, Benchun Miao, Elizabeth I. Buchbinder, Mei-Ju Su, Dirk Schadendorf, Itay Tirosh, Monika S. Kowalczyk, Abhay Kanodia, Charles H. Yoon, Patrick Hwu, Livnat Jerby, Bruce E. Johnson, Claire Margolais, Genevieve M. Boland, Bastian Schilling, Stephen Hodi, Russell S. Jenkins, Chantale Bernatchez, Riz Haq, Patrick A. Ott, Orit Rosenblatt-Rozen, Bokang Rabasha, Christopher Rodman, Benjamin Izar, Asaf Rotem, Dennie T. Frederick, Israel Cañadas, Meenhard Herlyn, Keith T. Flaherty, Ryan J. Sullivan, Alex K. Shalek, Shaolin Mei, Michael S. Cuoco
Publikováno v:
Cancer Immunology Research. 7:A082-A082
Immune checkpoint inhibitors (ICI) produce durable responses in some melanoma patients, but many patients derive no clinical benefit. The molecular underpinnings of ICI resistance involve intricate cell-cell interactions that are yet elusive. To syst
Autor:
Claire Margolais, Johannes C. Melms, David Liu, Gao Zhang, Asaf Rotem, Aviv Regev, Shaolin Mei, Bokang Rabasha, Peter K. Sorger, Rachel Leeson, Patrick Hwu, Marie Andrée Forget, Michael S. Cuoco, Israel Cañadas, Alex K. Shalek, Orit Rozenblatt-Rosen, F. Stephen Hodi, Kai W. Wucherpfennig, Levi A. Garraway, Dirk Schadendorf, Chantale Bernatchez, Orr Ashenberg, Parin Shah, Meenhard Herlyn, Elizabeth I. Buchbinder, Monika S. Kowalczyk, Ryan J. Sullivan, Tabea Moll, Adam N.R. Cartwright, Dennie T. Frederick, Benjamin Izar, Rizwan Haq, David A. Barbie, Benchun Miao, Mei-Ju Su, Rohit Thummalapalli, Russell W. Jenkins, Eliezer M. Van Allen, Shu Wang, Itay Tirosh, Genevieve M. Boland, Bastian Schilling, Livnat Jerby-Arnon, Jia-Ren Lin, Christopher Rodman, Keith T. Flaherty, Adrienne M. Luoma, Abhay Kanodia, Patrick A. Ott, Charles H. Yoon, Bruce E. Johnson, Shruti Malu
Publikováno v:
PMC
Immune checkpoint inhibitors (ICIs) produce durable responses in some melanoma patients, but many patients derive no clinical benefit, and the molecular underpinnings of such resistance remain elusive. Here, we leveraged single-cell RNA sequencing (s
Autor:
Daniel N. Cagney, Brian M. Alexander, F. Stephen Hodi, Elizabeth I. Buchbinder, Patrick A. Ott, Ayal A. Aizer
Publikováno v:
Journal of neuro-oncology. 129(3)
Novel systemic therapies with anti-tumor activity in the brain including small molecules targeting BRAF and MEK, and immune checkpoint inhibition, offer the possibility of improved control of intracranial disease. A number of prospective trials suppo
Autor:
Jeffrey S. Weber, Theodore F. Logan, Elmer Berghorn, Jeffrey A. Sosman, Suresh G. Nair Md, Donald P. Lawrence, Leslie A. Fecher, Christine Horak, George Kong, Lynn M. Schuchter, Craig L. Slingluff, Geoff Gibney, Joel Jiang, F. Stephen Hodi, Elizabeth I. Buchbinder, Mary Ruisi, Ryan J. Sullivan
Publikováno v:
The Lancet. Oncology. 17(7)
Summary Background Concurrent administration of the immune checkpoint inhibitors nivolumab and ipilimumab has shown greater efficacy than either agent alone in patients with advanced melanoma, albeit with more high-grade adverse events. We assessed w
Publikováno v:
Nature reviews. Clinical oncology. 13(2)
The relationship between cancer and the immune system is complex and provides unique therapeutic opportunities. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a regulatory molecule that suppresses T cell effector function following initial activation b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74cdb66678a5aed8cc5df3d17b7fb4a6
https://europepmc.org/articles/PMC4588295/
https://europepmc.org/articles/PMC4588295/
Autor:
Michael Goldstein, Mandeep S. Sawhney, Tara S. Kent, Anand Mahadevan, Andrea J. Bullock, Charles M. Vollmer, Mark P. Callery, Elizabeth I. Buchbinder, Rebecca A. Miksad, Ryan J. Sullivan, Douglas K. Pleskow
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 81:e615-e622
Purpose Stereotactic body radiotherapy (SBRT) has been used successfully to treat patients with locally advanced pancreas cancer. However, many patients develop metastatic disease soon after diagnosis and may receive little benefit from such therapy.
Autor:
Rene Gonzales, Jiaxin Niu, Jason J. Luke, Theresa Medina, Aaron H. Morris, Antoni Ribas, David J. Mauro, John M. Kirkwood, Kim Margolin, Elizabeth I. Buchbinder, Mohammed M. Milhem, Arthur M. Krieg, Inderjit Mehmi, Ryan M. Weight, Montaser Shaheen
Publikováno v:
Cancer Research. 78:CT144-CT144
Background: CMP-001 comprises a CpG-A oligodeoxynucleotide packaged within a virus-like particle. It is designed to activate tumor-associated plasmacytoid dendritic cells via TLR9 inducing an interferon-rich tumor microenvironment and anti-tumor CD8+
Autor:
Andrea Forschner, Elizabeth I. Buchbinder, Paolo A. Ascierto, Serigne Lo, Douglas B. Johnson, Lisa Zimmer, Jessica C. Hassel, Naima Benannoune, Peter Kölblinger, Justine V. Cohen, Zeynep Eroglu, Chloe Khoo, Simone M. Goldinger, Elisa A. Rozeman, Alexander M. Menzies, Anja Gesierich, Ralf Gutzmer, Meredith Ann McKean, Christoph Hoeller, Reinhard Dummer
Publikováno v:
Journal of Clinical Oncology. 36:e21588-e21588
e21588Background: Immune checkpoint inhibitors are standard of care for most patients (pts) with MM, yet only a minority has durable disease control. CTX has limited activity when used first-line, ...